Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst (NASDAQ:EWTX)

Group 1 - The article discusses Edgewise Therapeutics, Inc. (EWTX) and its ongoing development of EDG-7500 despite safety concerns related to atrial fibrillation (AF) [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and provides in-depth analysis of pharmaceutical companies through the Biotech Analysis Central service [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Edgewise Therapeutics or its products [1][3][4]